ImmuPharma (LON:IMM) Trading 15.7% Higher – Still a Buy?

Shares of ImmuPharma plc (LON:IMM) rose 15.7% during mid-day trading on Friday . The company traded as high as GBX 2.66 ($0.04) and last traded at GBX 2.37 ($0.03). Approximately 11,117,685 shares were traded during mid-day trading, an increase of 67% from the average daily volume of 6,674,517 shares. The stock had previously closed at GBX 2.05 ($0.03).

ImmuPharma Stock Up 11.2%

The stock’s 50 day moving average price is GBX 2.52 and its two-hundred day moving average price is GBX 3.04. The firm has a market capitalization of £9.69 million, a price-to-earnings ratio of -3.94 and a beta of 1.53.

ImmuPharma (LON:IMM) last posted its earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.